Quantitative Evaluation of the Economic Impact of Antimicrobial Resistance on the Treatment of Community-Acquired Acute Pyelonephritis in Korea
- PMID: 36047300
- PMCID: PMC9533169
- DOI: 10.3947/ic.2022.0057
Quantitative Evaluation of the Economic Impact of Antimicrobial Resistance on the Treatment of Community-Acquired Acute Pyelonephritis in Korea
Abstract
Background: The proportion of antimicrobial-resistant Enterobacteriales as a causative pathogen of community-acquired acute pyelonephritis (APN) has been increasing. The aim of this study was to quantitatively evaluate the impact of antimicrobial resistance on medical costs and length of hospital stay for the treatment of APN.
Materials and methods: A single-center retrospective cohort study was conducted between January 2018 and December 2019. All hospitalized patients aged ≥19 years who were diagnosed with community-acquired APN were recruited, and those diagnosed with Enterobacteriales as a causative pathogen were included. Log-linear regression analysis was performed to determine the risk factors for medical costs and length of hospital stay.
Results: A total of 241 patients participated in this study. Of these, 75 (31.1%) and 87 (36.1%) had extended-spectrum beta-lactamase (ESBL)-producing pathogens and ciprofloxacin-resistant pathogens as the causative pathogen, respectively. Based on the log-linear regression model, ESBL-producing Enterobacteriales is a causative pathogen that is, on average, 27.0%, or United States Dollar (USD) 1,211 (P = 0.026) more expensive than non-ESBL-producing Enterobacteriales. A patient who is a year older would incur USD 23 (P = 0.040) more, those having any structural problems in the urinary tract would incur USD 1,231 (P = 0.015) more, and those with a unit increase in the Pitt bacteremia score would incur USD 767 (P <0.001) more, with all other variables constant. Having a case in which ESBL-producing Enterobacteriales is a causative pathogen would explain staying 22.0% longer or 2 more days (P = 0.050) in the hospital than non-ESBL-producing Enterobacteriales. A patient who is 10 years older would, on average, would have to stay for half a day longer (P = 0.045). Any structural problems in the urinary tract explain a longer stay (2.4 days longer; P = 0.032), and moving from 0 to 5 on the Pitt bacteremia score would explain four more days (P = 0.038) in the hospital.
Conclusion: Patients with community-acquired APN with ESBL-producing Enterobacteriale as the causative pathogen would incur, on average, 27.0% higher medical costs and 22.0% longer hospitalization days than patients detected with non-ESBL-producing pathogens.
Keywords: Acute pyelonephritis; Antimicrobial resistance; Hospitalization; Medical costs.
Copyright © 2022 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS.
Conflict of interest statement
No conflict of interest.
Figures
Similar articles
-
Clinical effectiveness of oral antimicrobial therapy for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales.Eur J Clin Microbiol Infect Dis. 2020 Jan;39(1):159-167. doi: 10.1007/s10096-019-03705-w. Epub 2019 Sep 13. Eur J Clin Microbiol Infect Dis. 2020. PMID: 31520270
-
Inappropriate empirical antibiotic therapy does not adversely affect the clinical outcomes of patients with acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales.Eur J Clin Microbiol Infect Dis. 2019 May;38(5):937-944. doi: 10.1007/s10096-019-03528-9. Epub 2019 Mar 13. Eur J Clin Microbiol Infect Dis. 2019. PMID: 30868326
-
Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea.Infection. 2013 Jun;41(3):603-12. doi: 10.1007/s15010-013-0441-z. Epub 2013 Mar 16. Infection. 2013. PMID: 23504297
-
Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone.Microb Drug Resist. 2014 Feb;20(1):39-44. doi: 10.1089/mdr.2013.0075. Epub 2013 Aug 13. Microb Drug Resist. 2014. PMID: 23941639
-
Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.Postgrad Med. 2020 Apr;132(3):234-250. doi: 10.1080/00325481.2019.1680052. Epub 2019 Oct 24. Postgrad Med. 2020. PMID: 31608743 Review.
Cited by
-
Current Status and Prospect of Qualitative Assessment of Antibiotics Prescriptions.Infect Chemother. 2022 Dec;54(4):599-609. doi: 10.3947/ic.2022.0158. Infect Chemother. 2022. PMID: 36596676 Free PMC article. Review.
-
Implementing antimicrobial stewardship: lessons and perspectives from a university-affiliated tertiary hospital in Korea.Korean J Intern Med. 2024 May;39(3):399-412. doi: 10.3904/kjim.2023.504. Epub 2024 Apr 30. Korean J Intern Med. 2024. PMID: 38715230 Free PMC article.
-
Economic Burden of Community-Acquired Antibiotic-Resistant Urinary Tract Infections: Systematic Review and Meta-Analysis.JMIR Public Health Surveill. 2024 Oct 9;10:e53828. doi: 10.2196/53828. JMIR Public Health Surveill. 2024. PMID: 39382601 Free PMC article.
-
The Economics of Antibiotic Resistance: A Systematic Review and Meta-analysis Based on Global Research.Appl Health Econ Health Policy. 2025 Aug 30. doi: 10.1007/s40258-025-01001-7. Online ahead of print. Appl Health Econ Health Policy. 2025. PMID: 40884690
References
-
- Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J, Jr Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:155–164. - PubMed
-
- Kuehn BM. Alarming antimicrobial resistance trends emerge globally. JAMA. 2020;324:223. - PubMed
-
- Carlet J, Jarlier V, Acar J, Debaere O, Dehaumont P, Grandbastien B, Le Coz P, Lina G, Pean Y, Rambaud C, Roblot F, Salomon J, Schlemmer B, Tattevin P, Vallet B. Trends in antibiotic consumption and resistance in France over 20 years: Large and continuous efforts but contrasting results. Open Forum Infect Dis. 2020;7:ofaa452. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous